From: Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
Baseline characteristic | Patients who received HCV treatment (n = 17) | Patients who did not receive HCV treatment (n = 48) | All patients (N = 65) |
---|---|---|---|
Male sex - n (%) | 13 (76) | 30 (62) | 43 (66) |
Age, years – median (IQR) | 46 (42–49) | 46 (43–50) | 46 (43–50) |
HIV acquired by IDU – n (%) | 12 (70) | 45 (94) | 57 (88) |
Nadir, cells/mm3 – median (IQR) | 199 (76–292) | 121 (45–225) | 136 (52–242) |
CD4+ cells/mm3 – median (IQR) | 294 (216–482) | 258 (160–423) | 293 (165–424) |
CDC disease category C (%) | 6 (35) | 16 (33) | 22 (34) |
cART (%) | 16 (94) | 40 (83) | 56 (86) |
HIV-RNA < 5 0 copies/mL (%) | 10 (59) | 37 (77) | 47 (71) |
HBsAg-positive – n (%) | 0 (0) | 5(10) | 5 (8) |
Alcohol intake > 50 g/day – n (%) | 2 (12) | 11 (23) | 13 (20) |
First decompensation – n (%) | |||
Ascites | 14 (82) | 40 (83) | 54 (83) |
Variceal bleeding | 2 (12) | 3 (6) | 5 (8) |
Hepatic encephalopathy | 0 (0) | 5 (10) | 5 (8) |
Non-obstructive jaundice | 1 (6) | 0 (0) | 1 (1) |
Hepatocellular carcinoma – median (IQR) | 1 (6) | 2 (4) | 3 (4.6) |
Esophageal varices – n (%) | |||
Yes | 5 (29) | 25 (52) | 30 (15) |
No | 8 (47) | 9 (19) | 17 (2) |
Unknown | 4 (23) | 14 (29) | 18 (28) |
Child-Pugh score – median (IQR) | 7 (5–9) | 7 (6–8) | 7 (5–8) |
MELD score – median (IQR) | 11 (7.5–15.5) | 11 (7–14) | 11 (7–14) |
Serum albumin, g/dL – median (IQR) | 3.5 (2.4–4.2) | 3.0 (2.5–3.7) | 3.1 (2.5–3.9) |
FIB-4 value – median (IQR) | 6.5 (3.1–13.5) | 6.4 (4.2–10.6) | 6.4 (3.8–10.6) |
Liver stiffness, kPa – median (IQR) | 50 (34–70) | 48 (35–63) | 48 (35–64) |
LSPS – median (IQR) | 8.8 (4.9–17.4) | 10.5 (8–16.3) | 10.3 (7.6–16.4) |
HCV genotype – median (IQR) | |||
1 | 12 (70) | 26 (54) | 38 (58) |
2 | 0 (0) | 1 (2) | 1 (1.5) |
3 | 3 (18) | 9 (19) | 12 (18.5) |
4 | 2 (12) | 3 (6) | 5 (7.7) |
Unknown | 0 (0) | 9 (19) | 9 (13.8) |